vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $329.5M, roughly 1.5× Andersons, Inc.). Andersons, Inc. runs the higher net margin — 20.5% vs 6.8%, a 13.6% gap on every dollar of revenue. On growth, Pediatrix Medical Group, Inc. posted the faster year-over-year revenue change (-1.7% vs -2.4%). Over the past eight quarters, Pediatrix Medical Group, Inc.'s revenue compounded faster (-0.1% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
ANDE vs MD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $493.8M |
| Net Profit | $67.4M | $33.7M |
| Gross Margin | 70.3% | — |
| Operating Margin | 26.6% | 9.9% |
| Net Margin | 20.5% | 6.8% |
| Revenue YoY | -2.4% | -1.7% |
| Net Profit YoY | 49.6% | 10.5% |
| EPS (diluted) | — | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $493.8M | ||
| Q3 25 | $295.8M | $492.9M | ||
| Q2 25 | $535.0M | $468.8M | ||
| Q1 25 | $370.8M | $458.4M | ||
| Q4 24 | $337.5M | $502.4M | ||
| Q3 24 | $231.9M | $511.2M | ||
| Q2 24 | $492.5M | $504.3M | ||
| Q1 24 | $341.4M | $495.1M |
| Q4 25 | $67.4M | $33.7M | ||
| Q3 25 | $20.1M | $71.7M | ||
| Q2 25 | $7.9M | $39.3M | ||
| Q1 25 | $284.0K | $20.7M | ||
| Q4 24 | $45.1M | $30.5M | ||
| Q3 24 | $27.4M | $19.4M | ||
| Q2 24 | $36.0M | $-153.0M | ||
| Q1 24 | $5.6M | $4.0M |
| Q4 25 | 70.3% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 76.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 37.6% | — |
| Q4 25 | 26.6% | 9.9% | ||
| Q3 25 | 8.7% | 13.8% | ||
| Q2 25 | 4.6% | 12.8% | ||
| Q1 25 | 0.9% | 7.0% | ||
| Q4 24 | 19.9% | 7.8% | ||
| Q3 24 | 26.8% | 6.6% | ||
| Q2 24 | 11.6% | -31.3% | ||
| Q1 24 | 4.1% | 3.2% |
| Q4 25 | 20.5% | 6.8% | ||
| Q3 25 | 6.8% | 14.5% | ||
| Q2 25 | 1.5% | 8.4% | ||
| Q1 25 | 0.1% | 4.5% | ||
| Q4 24 | 13.4% | 6.1% | ||
| Q3 24 | 11.8% | 3.8% | ||
| Q2 24 | 7.3% | -30.3% | ||
| Q1 24 | 1.6% | 0.8% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | $0.59 | $0.84 | ||
| Q2 25 | $0.23 | $0.46 | ||
| Q1 25 | $0.01 | $0.24 | ||
| Q4 24 | $1.31 | $0.37 | ||
| Q3 24 | $0.80 | $0.23 | ||
| Q2 24 | $1.05 | $-1.84 | ||
| Q1 24 | $0.16 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $375.2M |
| Total DebtLower is stronger | $560.0M | $570.5M |
| Stockholders' EquityBook value | $1.2B | $865.9M |
| Total Assets | $3.7B | $2.2B |
| Debt / EquityLower = less leverage | 0.45× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $375.2M | ||
| Q3 25 | — | $340.1M | ||
| Q2 25 | — | $224.7M | ||
| Q1 25 | — | $99.0M | ||
| Q4 24 | $561.8M | $229.9M | ||
| Q3 24 | — | $103.8M | ||
| Q2 24 | — | $19.4M | ||
| Q1 24 | — | $8.0M |
| Q4 25 | $560.0M | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | $608.2M | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $865.9M | ||
| Q3 25 | $1.2B | $890.7M | ||
| Q2 25 | $1.4B | $833.8M | ||
| Q1 25 | $1.4B | $789.2M | ||
| Q4 24 | $1.4B | $764.9M | ||
| Q3 24 | $1.3B | $732.5M | ||
| Q2 24 | $1.3B | $706.5M | ||
| Q1 24 | $1.3B | $856.2M |
| Q4 25 | $3.7B | $2.2B | ||
| Q3 25 | $3.3B | $2.2B | ||
| Q2 25 | $3.4B | $2.1B | ||
| Q1 25 | $3.8B | $2.0B | ||
| Q4 24 | $4.1B | $2.2B | ||
| Q3 24 | $3.4B | $2.1B | ||
| Q2 24 | $3.3B | $2.0B | ||
| Q1 24 | $3.3B | $2.2B |
| Q4 25 | 0.45× | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | 0.45× | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $114.1M |
| Free Cash FlowOCF − Capex | $-77.1M | — |
| FCF MarginFCF / Revenue | -23.4% | — |
| Capex IntensityCapex / Revenue | 21.5% | — |
| Cash ConversionOCF / Net Profit | -0.09× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $114.1M | ||
| Q3 25 | $233.9M | $137.3M | ||
| Q2 25 | $299.3M | $137.2M | ||
| Q1 25 | $-350.0M | $-117.5M | ||
| Q4 24 | $268.8M | $133.0M | ||
| Q3 24 | $-2.1M | $91.8M | ||
| Q2 24 | $304.4M | $107.0M | ||
| Q1 24 | $-239.6M | $-125.2M |
| Q4 25 | $-77.1M | — | ||
| Q3 25 | $167.0M | — | ||
| Q2 25 | $250.5M | — | ||
| Q1 25 | $-396.6M | — | ||
| Q4 24 | $212.9M | — | ||
| Q3 24 | $-40.0M | — | ||
| Q2 24 | $275.8M | — | ||
| Q1 24 | $-266.4M | — |
| Q4 25 | -23.4% | — | ||
| Q3 25 | 56.5% | — | ||
| Q2 25 | 46.8% | — | ||
| Q1 25 | -106.9% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | -17.2% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | -78.0% | — |
| Q4 25 | 21.5% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 9.1% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 16.3% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 7.8% | — |
| Q4 25 | -0.09× | 3.39× | ||
| Q3 25 | 11.61× | 1.91× | ||
| Q2 25 | 38.10× | 3.49× | ||
| Q1 25 | -1232.46× | -5.66× | ||
| Q4 24 | 5.96× | 4.36× | ||
| Q3 24 | -0.08× | 4.72× | ||
| Q2 24 | 8.46× | — | ||
| Q1 24 | -42.94× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
